Sarcoma Drugs Market By Disease Indication (Malignant bone tumors, Soft tissue sarcoma), By Treatment (Chemotherapy, Targeted drug therapy), By End User (Hospital and clinics, Cancer research center): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global sarcoma drugs market was valued at $1,127 million in 2021, and is projected to reach $2,497.1 million by 2031, growing at a CAGR of 8.3% from 2022 to 2031. Sarcoma is a form of cancer that develops in soft tissues such as cartilage, fat, muscle, blood vessels, fibrous tissue, and other connective or supportive tissues as well as in bone. Based on where the cancer develops, there are various varieties of sarcoma. For instance, rhabdomyosarcoma develops in muscles, liposarcoma develops in fat, and osteosarcoma develops in bones. The type and grade of the cancer determines course of treatment and prognosis (how abnormal the cancer cells look under a microscope and how quickly the cancer is likely to grow and spread). Both children and adults can develop sarcoma. Chemotherapy and targeted therapy are two treatment options available for sarcoma treatment.
The sarcoma drugs market is driven by rise in prevalence of cancer, technological advancements in development of sarcoma drugs, and rise in number of product launches and approvals for sarcoma drugs. For instance, according to the World Cancer Research Fund International, it was reported that 18,094,716 cancer cases were diagnosed across the globe. In addition, rise in prevalence of soft tissue sarcoma fuels demand for sarcoma drugs for treatment purpose. Thus, this factor is anticipated to drive growth of the sarcoma drugs market. For instance, according to the American Cancer Society, in 2022, it was estimated that about 13,190 new soft tissue sarcomas will be diagnosed, among them 7,590 in males and 5,600 in females in the U.S. in 2022. As per the same source, it was estimated that around 5,130 people (2,740 males and 2,390 females) are expected to die of soft tissue sarcomas.
The global sarcoma drugs market is predicted to develop as more patients battle soft tissue sarcoma, which causes increase in shift of consumer preference toward medicinal treatment over surgical procedures. The use of chemotherapy and targeted therapy supported by a number of advantages, including quicker healing, lower morbidity and mortality, and shorter hospital stays.
Geriatric population is more susceptible to chronic diseases such as cancer. Rise in number of geriatric populations increases demand of sarcoma drugs for cancer treatment. Thus, this factor contributes toward growth of the sarcoma drugs market. In addition, governments globally have increased the expenditure on the healthcare sector. For instance, according to the Centers for Medicare & Medicaid Services, the U.S. health care spending grew by 9.7% from 2019 to 2020, reaching $4.1 trillion ($12,530 per person). Similarly, as per the Office for National Statistics, total healthcare expenditure in the UK accounted for 12.8% of the gross domestic product (GDP) in 2020, compared to 10.2% in 2019. Furthermore, it has been estimated that approximately 30% of the healthcare expenditure is used in upgrading the healthcare infrastructure, especially medical equipment used at public health centers (hospitals). Hence, this rise in healthcare expenditure across the globe is expected to fuel demand for sarcoma drugs in different disease treatments, which boosts the market growth.
On the other hand, high cost associated with sarcoma drugs and side effects of chemotherapy hinder the market growth.
The global sarcoma drugs market is segmented on the basis of disease indication, treatment, end user, and region. On the basis of type the market is segmented into malignant bone tumors and soft tissue sarcoma. The soft tissue sarcoma segment is further sub-segmented into dermatofibrosarcoma, leiomyosarcoma, synovial cell sarcoma, rhabdomyosarcoma, and others. On the basis of treatment, the market is segmented into chemotherapy and targeted drug therapy. By end user, it is bifurcated into hospitals & clinics and cancer research centers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global sarcoma drugs market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Hoffmann-La Roche AG., Daiichi Sankyo Company, Limited., AgonOX, Inc. and Eisai Co., Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sarcoma drugs market analysis from 2021 to 2031 to identify the prevailing sarcoma drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the sarcoma drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global sarcoma drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Indication
Malignant bone tumors
Soft tissue sarcoma
Type
Dermatofibro sarcoma
Leiomyosarcoma
Synovial cell sarcoma
Rhabdomyo sarcoma
Others
By Treatment
Chemotherapy
Targeted drug therapy
By End User
Hospital and clinics
Cancer research center
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Baxter Healthcare Corporation
BRISTOL-MYERS SQUIBB COMPANY
Daiichi Sankyo Company, Limited
AgonOX, Inc.
Eisai Co., Ltd.
GlaxoSmithKline, plc.
Hoffmann-La Roche AG.
Johnson and Johnson
MERCK & CO., INC.
Novartis AG
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: SARCOMA DRUGS MARKET, BY DISEASE INDICATION
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Malignant bone tumors
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Soft tissue sarcoma
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Soft tissue sarcoma Sarcoma Drugs Market by Type
- 4.3.4.1 Dermatofibro sarcoma Market size and forecast, by region
- 4.3.4.2 Leiomyosarcoma Market size and forecast, by region
- 4.3.4.3 Synovial cell sarcoma Market size and forecast, by region
- 4.3.4.4 Rhabdomyo sarcoma Market size and forecast, by region
- 4.3.4.5 Others Market size and forecast, by region
- CHAPTER 5: SARCOMA DRUGS MARKET, BY TREATMENT
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Chemotherapy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Targeted drug therapy
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: SARCOMA DRUGS MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital and clinics
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Cancer research center
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: SARCOMA DRUGS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Disease Indication
- 7.2.2.1 North America Soft tissue sarcoma Sarcoma Drugs Market by Type
- 7.2.3 North America Market size and forecast, by Treatment
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Disease Indication
- 7.2.5.1.2 Market size and forecast, by Treatment
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Disease Indication
- 7.2.5.2.2 Market size and forecast, by Treatment
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Disease Indication
- 7.2.5.3.2 Market size and forecast, by Treatment
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Disease Indication
- 7.3.2.1 Europe Soft tissue sarcoma Sarcoma Drugs Market by Type
- 7.3.3 Europe Market size and forecast, by Treatment
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Disease Indication
- 7.3.5.1.2 Market size and forecast, by Treatment
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Disease Indication
- 7.3.5.2.2 Market size and forecast, by Treatment
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Disease Indication
- 7.3.5.3.2 Market size and forecast, by Treatment
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Disease Indication
- 7.3.5.4.2 Market size and forecast, by Treatment
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Disease Indication
- 7.3.5.5.2 Market size and forecast, by Treatment
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Disease Indication
- 7.3.5.6.2 Market size and forecast, by Treatment
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Disease Indication
- 7.4.2.1 Asia-Pacific Soft tissue sarcoma Sarcoma Drugs Market by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Disease Indication
- 7.4.5.1.2 Market size and forecast, by Treatment
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Disease Indication
- 7.4.5.2.2 Market size and forecast, by Treatment
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Disease Indication
- 7.4.5.3.2 Market size and forecast, by Treatment
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Disease Indication
- 7.4.5.4.2 Market size and forecast, by Treatment
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Disease Indication
- 7.4.5.5.2 Market size and forecast, by Treatment
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Disease Indication
- 7.4.5.6.2 Market size and forecast, by Treatment
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Disease Indication
- 7.5.2.1 LAMEA Soft tissue sarcoma Sarcoma Drugs Market by Type
- 7.5.3 LAMEA Market size and forecast, by Treatment
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Disease Indication
- 7.5.5.1.2 Market size and forecast, by Treatment
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Disease Indication
- 7.5.5.2.2 Market size and forecast, by Treatment
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Disease Indication
- 7.5.5.3.2 Market size and forecast, by Treatment
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Disease Indication
- 7.5.5.4.2 Market size and forecast, by Treatment
- 7.5.5.4.3 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Baxter Healthcare Corporation
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 BRISTOL-MYERS SQUIBB COMPANY
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Daiichi Sankyo Company, Limited
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 AgonOX, Inc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Eisai Co., Ltd.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 GlaxoSmithKline, plc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Hoffmann-La Roche AG.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Johnson and Johnson
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 MERCK & CO., INC.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Novartis AG
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 2. SARCOMA DRUGS MARKET, FOR MALIGNANT BONE TUMORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. SARCOMA DRUGS MARKET FOR MALIGNANT BONE TUMORS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. SARCOMA DRUGS MARKET, FOR SOFT TISSUE SARCOMA, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. SARCOMA DRUGS MARKET FOR SOFT TISSUE SARCOMA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. GLOBAL SOFT TISSUE SARCOMA SARCOMA DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 7. SARCOMA DRUGS MARKET, FOR DERMATOFIBRO SARCOMA, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. SARCOMA DRUGS MARKET, FOR LEIOMYOSARCOMA, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. SARCOMA DRUGS MARKET, FOR SYNOVIAL CELL SARCOMA, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. SARCOMA DRUGS MARKET, FOR RHABDOMYO SARCOMA, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. SARCOMA DRUGS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. GLOBAL SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 13. SARCOMA DRUGS MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. SARCOMA DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. SARCOMA DRUGS MARKET, FOR TARGETED DRUG THERAPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. SARCOMA DRUGS MARKET FOR TARGETED DRUG THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. GLOBAL SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 18. SARCOMA DRUGS MARKET, FOR HOSPITAL AND CLINICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. SARCOMA DRUGS MARKET FOR HOSPITAL AND CLINICS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 20. SARCOMA DRUGS MARKET, FOR CANCER RESEARCH CENTER, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. SARCOMA DRUGS MARKET FOR CANCER RESEARCH CENTER, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 22. SARCOMA DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. NORTH AMERICA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 24. NORTH AMERICA SOFT TISSUE SARCOMA SARCOMA DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 25. NORTH AMERICA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 26. NORTH AMERICA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 27. NORTH AMERICA SARCOMA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 28. U.S. SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 29. U.S. SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 30. U.S. SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 31. CANADA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 32. CANADA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 33. CANADA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 34. MEXICO SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 35. MEXICO SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 36. MEXICO SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 37. EUROPE SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 38. EUROPE SOFT TISSUE SARCOMA SARCOMA DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 39. EUROPE SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 40. EUROPE SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 41. EUROPE SARCOMA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 42. GERMANY SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 43. GERMANY SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 44. GERMANY SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 45. FRANCE SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 46. FRANCE SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 47. FRANCE SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 48. UK SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 49. UK SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 50. UK SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 51. ITALY SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 52. ITALY SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 53. ITALY SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 54. SPAIN SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 55. SPAIN SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 56. SPAIN SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 57. REST OF EUROPE SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 58. REST OF EUROPE SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 59. REST OF EUROPE SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 60. ASIA-PACIFIC SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 61. ASIA-PACIFIC SOFT TISSUE SARCOMA SARCOMA DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 62. ASIA-PACIFIC SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 63. ASIA-PACIFIC SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 64. ASIA-PACIFIC SARCOMA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 65. CHINA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 66. CHINA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 67. CHINA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 68. JAPAN SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 69. JAPAN SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 70. JAPAN SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 71. INDIA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 72. INDIA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 73. INDIA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 74. AUSTRALIA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 75. AUSTRALIA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 76. AUSTRALIA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 77. SOUTH KOREA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 78. SOUTH KOREA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 79. SOUTH KOREA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 80. REST OF ASIA-PACIFIC SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 81. REST OF ASIA-PACIFIC SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 82. REST OF ASIA-PACIFIC SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 83. LAMEA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 84. LAMEA SOFT TISSUE SARCOMA SARCOMA DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 85. LAMEA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 86. LAMEA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 87. LAMEA SARCOMA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 88. BRAZIL SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 89. BRAZIL SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 90. BRAZIL SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 91. SAUDI ARABIA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 92. SAUDI ARABIA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 93. SAUDI ARABIA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 94. SOUTH AFRICA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 95. SOUTH AFRICA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 96. SOUTH AFRICA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 97. REST OF LAMEA SARCOMA DRUGS MARKET, BY DISEASE INDICATION, 2021-2031 ($MILLION)
- TABLE 98. REST OF LAMEA SARCOMA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 99. REST OF LAMEA SARCOMA DRUGS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 100.BAXTER HEALTHCARE CORPORATION: COMPANY SNAPSHOT
- TABLE 101.BAXTER HEALTHCARE CORPORATION: OPERATING SEGMENTS
- TABLE 102.BAXTER HEALTHCARE CORPORATION: PRODUCT PORTFOLIO
- TABLE 103.BAXTER HEALTHCARE CORPORATION: NET SALES,
- TABLE 104.BAXTER HEALTHCARE CORPORATION: KEY STRATERGIES
- TABLE 105.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 106.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
- TABLE 107.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- TABLE 108.BRISTOL-MYERS SQUIBB COMPANY: NET SALES,
- TABLE 109.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
- TABLE 110.DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT
- TABLE 111.DAIICHI SANKYO COMPANY, LIMITED: OPERATING SEGMENTS
- TABLE 112.DAIICHI SANKYO COMPANY, LIMITED: PRODUCT PORTFOLIO
- TABLE 113.DAIICHI SANKYO COMPANY, LIMITED: NET SALES,
- TABLE 114.DAIICHI SANKYO COMPANY, LIMITED: KEY STRATERGIES
- TABLE 115.AGONOX, INC.: COMPANY SNAPSHOT
- TABLE 116.AGONOX, INC.: OPERATING SEGMENTS
- TABLE 117.AGONOX, INC.: PRODUCT PORTFOLIO
- TABLE 118.AGONOX, INC.: NET SALES,
- TABLE 119.AGONOX, INC.: KEY STRATERGIES
- TABLE 120.EISAI CO., LTD.: COMPANY SNAPSHOT
- TABLE 121.EISAI CO., LTD.: OPERATING SEGMENTS
- TABLE 122.EISAI CO., LTD.: PRODUCT PORTFOLIO
- TABLE 123.EISAI CO., LTD.: NET SALES,
- TABLE 124.EISAI CO., LTD.: KEY STRATERGIES
- TABLE 125.GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT
- TABLE 126.GLAXOSMITHKLINE, PLC.: OPERATING SEGMENTS
- TABLE 127.GLAXOSMITHKLINE, PLC.: PRODUCT PORTFOLIO
- TABLE 128.GLAXOSMITHKLINE, PLC.: NET SALES,
- TABLE 129.GLAXOSMITHKLINE, PLC.: KEY STRATERGIES
- TABLE 130.HOFFMANN-LA ROCHE AG.: COMPANY SNAPSHOT
- TABLE 131.HOFFMANN-LA ROCHE AG.: OPERATING SEGMENTS
- TABLE 132.HOFFMANN-LA ROCHE AG.: PRODUCT PORTFOLIO
- TABLE 133.HOFFMANN-LA ROCHE AG.: NET SALES,
- TABLE 134.HOFFMANN-LA ROCHE AG.: KEY STRATERGIES
- TABLE 135.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
- TABLE 136.JOHNSON AND JOHNSON: OPERATING SEGMENTS
- TABLE 137.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
- TABLE 138.JOHNSON AND JOHNSON: NET SALES,
- TABLE 139.JOHNSON AND JOHNSON: KEY STRATERGIES
- TABLE 140.MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 141.MERCK & CO., INC.: OPERATING SEGMENTS
- TABLE 142.MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 143.MERCK & CO., INC.: NET SALES,
- TABLE 144.MERCK & CO., INC.: KEY STRATERGIES
- TABLE 145.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 146.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 147.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 148.NOVARTIS AG: NET SALES,
- TABLE 149.NOVARTIS AG: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.SARCOMA DRUGS MARKET SEGMENTATION
- FIGURE 2.SARCOMA DRUGS MARKET,2021-2031
- FIGURE 3.SARCOMA DRUGS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.SARCOMA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.SARCOMA DRUGS MARKET,BY DISEASE INDICATION,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF MALIGNANT BONE TUMORS SARCOMA DRUGS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SOFT TISSUE SARCOMA SARCOMA DRUGS MARKET,2021-2031(%)
- FIGURE 15.SARCOMA DRUGS MARKET,BY TREATMENT,2021(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY SARCOMA DRUGS MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF TARGETED DRUG THERAPY SARCOMA DRUGS MARKET,2021-2031(%)
- FIGURE 18.SARCOMA DRUGS MARKET,BY END USER,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL AND CLINICS SARCOMA DRUGS MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CANCER RESEARCH CENTER SARCOMA DRUGS MARKET,2021-2031(%)
- FIGURE 21.SARCOMA DRUGS MARKET BY REGION,2021
- FIGURE 22.U.S. SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 23.CANADA SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 24.MEXICO SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 25.GERMANY SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 26.FRANCE SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 27.UK SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 28.ITALY SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 29.SPAIN SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 30.REST OF EUROPE SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 31.CHINA SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 32.JAPAN SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 33.INDIA SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 34.AUSTRALIA SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 35.SOUTH KOREA SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 36.REST OF ASIA-PACIFIC SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 37.BRAZIL SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 38.SAUDI ARABIA SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 39.SOUTH AFRICA SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 40.REST OF LAMEA SARCOMA DRUGS MARKET,2021-2031($MILLION)
- FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 45.COMPETITIVE DASHBOARD
- FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 47.BAXTER HEALTHCARE CORPORATION.: NET SALES ,($MILLION)
- FIGURE 48.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ,($MILLION)
- FIGURE 49.DAIICHI SANKYO COMPANY, LIMITED.: NET SALES ,($MILLION)
- FIGURE 50.AGONOX, INC..: NET SALES ,($MILLION)
- FIGURE 51.EISAI CO., LTD..: NET SALES ,($MILLION)
- FIGURE 52.GLAXOSMITHKLINE, PLC..: NET SALES ,($MILLION)
- FIGURE 53.HOFFMANN-LA ROCHE AG..: NET SALES ,($MILLION)
- FIGURE 54.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
- FIGURE 55.MERCK & CO., INC..: NET SALES ,($MILLION)
- FIGURE 56.NOVARTIS AG.: NET SALES ,($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook